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ABSTRACT 
This study reviews the available Indian literature on buprenorphine abuse. Buprenorphine 
was introduced in 1986; the abuse, Hrst noticed in 1987, increased rapidly till 1994, and then decreased 
gradually. Initiated through other addicts and medical practitioners, the abuse was mostly as a 
cheap, easily and legally available substitute for opioids. The typical young adult male abuser used 
an intravenous cocktail with diazepam, pheneramine or promethazine for a better kick. The withdrawal 
syndrome was typical of the opioids and without an expected delayed onset. Complications of 
pseudoaneurysm and recurrent koro in repeated withdrawal were reported. Buprenorphine as a 
detoxifying agent for opioids reportedly gave better symptom control in the first week but high rates 
of dependence induction were reported. The Indian data tends to caution against the Western 
enthusiasm to use buprenorphine for detoxification or maintenance of opioid abusers. 
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Buprenorphine is a mixed agonist antagonist 
opioid, available in sublingual/oral and parenteral 
form. Developed in mid-seventies, in comparison 
to morphine, it was reported to be 25-40 times more 
potent analgesic, to have lower over dose lethality; 
to give euphoria which is less, and limited by a 
ceiling effect of higher doses; and to have a mild 
and delayed withdrawal. Hence, it was claimed to 
be a safe opioid with low abuse potential, and was 
recommended not only as an analgesic, but also 
as a drug for detoxification and maintenance 
treatment of opioid dependence (Jasinski et 
al.,1978. Banks, 1979; Mello & Mendelson.1980; 
Robertson etal., 1986). 
Beginning, in 1983, a number of reports 
have highlighted the abuse of buprenorphine in 
oral as well as parenteral forms and alone as 
well as in combination with benzodiazepines or 
antihistamines (Harper,1983; Strang, 1985; Stark 
etal,1987; O'Connor etal., 1988;Hammerseley 
et al.,1990). All the studies reported 
buprenorphine abuse primarily as a substitute 
abuse in heroin abusers. 
In India buprenorphine was introduced in 
1986. According to the published data, the first 
cases of buprenorphine abuse were registered 
in 1987 (Singh et al.,1992), presented in 
professional forums in 1989 (Basu et al., 1990) 
and published in 1990 (Basu et al.,1990; 
Chowdhury & Chowdhury, 1990; Nizamie & 
Sharma, 1990). Till date more than a dozen 
reports have been published covering various 
aspects of buprenorphine abuse. The present 
study aims to summarize the Indian research 
on the abuse of buprenorphine and its use in the 
treatment of opioid abusers. 
MATERIAL & METHOD 
The material for this study comprised of 
i) the published Indian studies on abuse of 
buprenorphine and its use in the treatment of 
opioid abusers, ii) the data on 145 cases of 
buprenorphine abuse seen in the Drug 
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De-addictiorf and Treatment Centre, Department 
of Psychiatry, Post Graduate Institute of Medical 
Education and Research, Chandigarh (Sharma 
& Mattoo, 1998) & iii) the data available from 
the Drug Controller of India on the production of 
buprenorphine. 
RESULTS 
Availability : Buprenorphine was 
introduced as a Schedule-H drug and listed In 
the Narcotic Drugs and Psychotropic Substances 
Act (NDPSA, 1985). As a Schedule-H drug it 
was to be dispensed only on the prescription of 
a registered medical practitioner. As a drug under 
the NDPS Act, it invited severe punishment for 
unauthorized possession or dealings. But, as with 
most other scheduled drugs, these provisions 
have never been effectively implemented. Thus, 
buprenorphine is almost freely available without 
a prescription. There have been no prosecutions 
for buprenorphine under the NDPS Act. 
Production : The only data available, 
provided by the Drug Controller of India, New 
Delhi (personal communication) listed the 
production, and presumably the sale, of 8.18 Kg 
in 1993-1994, 7.2 Kg in 1994-1995, 25.56 Kg in 
1995-1996 and 8.28 Kg in 1996-November 97 
periods. There is no explanation available for 
the sudden increase in production in 1995-1996; 
if some of it was exported or all consumed in 
the country. 
Prevalence of Abuse : The early 
publications covered 54, 7, and 18 cases 
respectively, comprising 7%, 10% and 17% of 
opioid, mostly heroin abusers seen over 2 years, 
6 months and 3 years respectively (Chowdhury 
& Chowdhury, 1990; Lai, 1991; Singh et ai., 
1992). More recently, series of 90 cases (51% 
of opioid abusers seen over 3 years) and 100 
cases have been reported (Umesh Babu & 
Chaturvedi, 1995; Vinay Kumar & Singh, 1996). 
Between 1987 and 1997, out of 687 cases of 
opioid abuse registered in our centre, 145 cases 
(20%) reported buprenorphine abuse • the 
percentage varying from 6 to 34 in different 
years, with the highest percentages being 
recorded between 1990 and 1994 and a slow 
decline being recorded since then (Sharma & 
Mattoo, 1998). 
Profile of Abuser: The typical profile of a 
buprenorphine abuser is of an urban, young to 
middle age (19-42 years) male, who has had 
some school or college education and, has a 
low to middle level occupation (Basu et al.,1990; 
Nizamie & Sharma, 1990; Singh et al.,1992; 
Tripathi et al.,1995; Sharma & Mattoo, 1998). 
Onset of Abuse : Most cases had 
graduated to buprenorphine abuse from the 
abuse of other opioids, heroin in up to 84% cases, 
which had preceded for a usual of 3-5 years and 
a maximum of 2-12 years (Basu et al.,1990; 
Chowdhury & Chowdhury, 1990; Nizamie 4 
Sharma, 1990; Singh et al.1992; Chavan et 
al.,1995; Umesh Babu & Chaturvedi, 1995; Vinay 
Kumar & Singh, 1996; Sharma & Mattoo, 1998). 
Reasons for Initiation : The common 
reasons given for changing over to 
buprenorphine abuse were - initially, non-
availability, and purity of the drug. The initiation 
was predominantly through fellow addicts and 
less often, by medical professionals for 
detoxification from other opioids (Basu et 
al.,1990; Chowdhury & Chowdhury, 1990; Lai, 
1991; Singh et al.1992; Umesh Babu & 
Chaturvedi, 1995; Vinay Kumar & Singh, 1996; 
Sharma & Mattoo, 1998). 
Pattern of Use: The reported duration of 
buprenorphine abuse has ranged from 4-36 
months, with a mean of 14 months, while the 
daily dose ranged from 1-7 mg, with a meanof 
3 mg (Singh et al.,1992). Except for two reports 
of abuse by mainly intramuscular and less often 
oral route (Chowdhury & Chowdhury, 1990; 
Nizamie & Sharma, 1990), all others have 
reported intravenous abuse in upto 86% cases 
(Sharma & Mattoo, 1998). Abuse of 
buprenorphine alone was reported in 13-54% 
cases (Chowdhury & Chowdhury, 1990; Gupta 
et al.,1996; Vinay Kumar & Singh, 1996; Sharma 
& Mattoo, 1998). The common and interesting 
co-abuse was of an intravenous cocktail of 0.6 
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mg of buprenorphine with 10-20 mg of diazepam 
or 45-90 mg of pheneramine or 100-200 mg of 
promethazine taken 2-4 times daily. Reportedly, 
compared to buprenorphine alone, the cocktail 
provide a more intense and prolonged kick (1-3 
hours instead of 1/2-1 hour) and in some cases 
also helped to suppress side-effects like nausea. 
This co-abuse was reported in 55% and 78% 
cases in one series (Singh et al.,1992; Sharma 
& Mattoo, 1998). The concurrent abuse of heroin 
was reported in 17%, 56% and 48-71% cases 
respectively (Singh et al.,1992; Vinay Kumar & 
Singh, 1996; Chowdhury & Chowdhury, 1990). 
An interesting finding reported by 2 out of 3 
concurrent heroin abusers was of a decrease in 
euphoria induced by heroin (Singh et al.,1992). 
Other reported co-abused substances were 
alcohol, cannabis and carisoprodol (Singh et 
al.,1992; Sharma & Mattoo, 1998). 
Withdrawal Syndrome; By self-reports as 
well as observation in hospitalized patients, 
buprenorphine withdrawal was reported to start 
in 1-2 days, peak after 2-4 days and last for 2-3 
weeks (Lai, 1991; Singh et al.,1992; Tripathi et 
al.,1995). Corresponding findings were reported 
for naloxone induced buprenorphine withdrawal 
(Nigam et al., 1994). The aches and pain 
reportedly tapered off over a longer period of up 
to 6 weeks and the withdrawal severity was 
subjectively one half of that of heroin (Singh et 
al., 1992). 
Risk Behaviours and Complications : A 
higher prevalence of high risk behaviours like 
unprotected sex, sex with multiple partners and 
commercial sex workers, homosexuality and, 
inadequate cleaning and sharing of injection 
material with multiple partners have all been 
reported for buprenorphine abusers (Malhotra et 
al.,1993). A case of recurrent koro in repeated 
intravenous buprenorphine withdrawal has also 
been reported (Chowdhury & Banerjee, 1996). 
Treatment Outcome : One study reported 
that by 3 visits or one year, 75% cases had 
dropped out of follow up and 60% cases had 
relapsed to heroin or buprenorphine abuse 
(Singh etal.. 1992). 
Buprenorphine for detoxifying heroin 
abusers : Two studies reported using 
buprenorphine to detoxify heroin and other opioid 
abusers (Chowdhury & Chowdhury, 1990; Nigam 
et al.,1993). But, with a regime of 0.3 mg 
intramuscular thrice, twice and once daily, 
dependence on injectable & oral buprenorphine 
were found to develop in 18% and 6% cases 
respectively (Chowdhury & Chowdhury, 1990). 
DISCUSSION 
The available production and sale data 
are inadequate for any meaningful interpretation. 
The reports of abuse coming from almost all over 
the country, indicate that buprenorphine is a 
nationwide phenomenon. 
In Ireland buprenorphine abuse" was 
recorded about 6 years following its introduction, 
and then showed very rapid increase among 
opioid abusers (O'Connor et al.,1988). In India 
the lag period between introduction and abuse 
was only one year and the increase among the 
opioid abusers was much slower. This has been 
attributed to a complex interaction of lax drug 
dispensing controls and lower and less intense 
prevalence of hard drugs including opioids 
(Singh et al.,1992). 
A typical buprenorphine abuser is an 
educated young adult urban male with a low to 
middle level occupation. A typical abuser has 
been an opioid abuser for some years before 
being introduced to buprenorphine abuse by 
fellow addicts and in a few cases by medical 
practitioners (for detoxification of an existing 
opioid abuse). The buprenorphine abuse is 
explained mainly by non availability of heroin 
and cheaper cost and also by easy and legal 
availability; reasons similar to the ones reported 
from the West (O'Connor et al.,1988). It implies 
that most abusers will prefer heroin to 
buprenorphine. 
Although initial abuse may be by 
intramuscular route, soon intravenous becomes 
the preferred route. The usual abuse is as a 
cocktail with diazepam, pheneramine or 
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promethazine, which gives a more intense and 
prolonged kick than buprenorphine alone - a 
pattern similar to that noted in West (Strang, 
1985; Stark et al., 1987; O'Connor et al.,1988; 
Hammerseley et al., 1990). The daily doses may 
range from 1-7 mg, much less than the doses at 
which opioid antagonist ceiling effects on 
euphoria become manifest; the ceiling effect may 
still be manifested as decreased concurrent 
heroin abuse (Jasinski et al.,1978; Mello & 
Mendelson, 1980; Walsh et al.,1994). 
The finding that buprenorphine withdrawal 
syndrome is of lesser severity than of heroin, 
but its course in typical of other opioids, is similar 
to that reported from the West (San et al.,1992). 
Thus, there is no substantiation of the initial 
expectations of the withdrawal being delayed by 
two weeks or so (Jasinski et al.,1978; Mello & 
Mendelson, 1980). 
Detoxification can be successfully 
completed in most cases by using clonidine and 
other symptomatic medications. But, as with 
other opioids, the treatment outcome remains 
poor, with high rates of drop out and relapse. 
Compared to clonidine, the use of 
buprenorphine to detoxify opioid abusers is 
marginally advantageous in providing better 
symptom control in the first week of the withdrawal 
(Cheskin et al.,1994; Janiri et al.,1994). But, it 
carries a high risk of introducing the patients to 
abuse of a new opioid. This is borne out by the 
onset of buprenorphine abuse following exposure 
to buprenorphine as a detoxifying agent in as 
many as 24% cases by clinical observation 
(Chowdhury & Chowdhury, 1990) and in 33% 
cases by self-report (Singh et al.,1992). 
The dose of abuse reported in India is within 
the limits of the ceiling effect of high doses on 
buprenorphine induced euphoria (Walsh et 
al.,1994). Thus, the inherent antagonistic effect 
may reduce the risk of high dose morbidity and 
mortality (Banks, 1979; Robertson et al.,1986), 
but does not decrease the abuse potential of 
buprenorphine. The Indian data shows that the 
health risks and social consequences of 
buprenorphine abuse are in no measure milder 
compared to the abuse of other opioids (Singh et 
al., 1992; Malhotra et al.,1993; Basu et al.,1994). 
In the West, more so in the USA. 
buprenorphine is being promoted as a 
detoxification and maintenance agent in opioid 
abuse (Ling et al.,1996). The Indian research 
findings suggest a need for caution in prescribing 
buprenorphine in opioid abuse as a detoxifying 
agent and may be also as a maintenance agent. 
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